BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23404110)

  • 21. The role of the TP73 gene and its transcripts in neuro-oncology.
    Jancalek R
    Br J Neurosurg; 2014 Oct; 28(5):598-605. PubMed ID: 24742294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
    Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
    Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers.
    Becker K; Pancoska P; Concin N; Vanden Heuvel K; Slade N; Fischer M; Chalas E; Moll UM
    Int J Oncol; 2006 Oct; 29(4):889-902. PubMed ID: 16964385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma.
    Gao Y; Yang M; Jiang Z; Woda BA; Mercurio AM; Qin J; Huang X; Zhang F
    Hum Pathol; 2014 Jun; 45(6):1184-91. PubMed ID: 24745619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p63 and p73: roles in development and tumor formation.
    Moll UM; Slade N
    Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.
    Zaika AI; Kovalev S; Marchenko ND; Moll UM
    Cancer Res; 1999 Jul; 59(13):3257-63. PubMed ID: 10397274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
    Vilgelm A; El-Rifai W; Zaika A
    Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 14-3-3sigma negatively regulates the cell cycle, and its down-regulation is associated with poor outcome in intrahepatic cholangiocarcinoma.
    Kuroda Y; Aishima S; Taketomi A; Nishihara Y; Iguchi T; Taguchi K; Maehara Y; Tsuneyoshi M
    Hum Pathol; 2007 Jul; 38(7):1014-1022. PubMed ID: 17391729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
    Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C
    Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73.
    Dietz S; Rother K; Bamberger C; Schmale H; Mössner J; Engeland K
    FEBS Lett; 2002 Aug; 525(1-3):93-9. PubMed ID: 12163168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors.
    Castillo J; Goñi S; Latasa MU; Perugorría MJ; Calvo A; Muntané J; Bioulac-Sage P; Balabaud C; Prieto J; Avila MA; Berasain C
    Gastroenterology; 2009 Nov; 137(5):1805-15.e1-4. PubMed ID: 19664633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma.
    Zhao W; Zhang B; Guo X; Zhang X; Hu J; Hu X; Lu Y
    Cancer Biomark; 2014; 14(4):197-202. PubMed ID: 24934361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dominant-negative interplay between p53, p63 and p73: A family affair.
    Billant O; Léon A; Le Guellec S; Friocourt G; Blondel M; Voisset C
    Oncotarget; 2016 Oct; 7(43):69549-69564. PubMed ID: 27589690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases.
    Laohaviroj M; Chamgramol Y; Pairojkul C; Mulvenna J; Sripa B
    Asian Pac J Cancer Prev; 2016; 17(1):201-5. PubMed ID: 26838210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 family members: similar biochemistry, different biology.
    Barbieri CE; Pietenpol JA
    Cancer Biol Ther; 2005 Apr; 4(4):419-20. PubMed ID: 15908776
    [No Abstract]   [Full Text] [Related]  

  • 36. Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma.
    Yonglitthipagon P; Pairojkul C; Bhudhisawasdi V; Mulvenna J; Loukas A; Sripa B
    Clin Biochem; 2012 Jul; 45(10-11):827-34. PubMed ID: 22552009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The C terminus of p53 family proteins is a cell fate determinant.
    Harms KL; Chen X
    Mol Cell Biol; 2005 Mar; 25(5):2014-30. PubMed ID: 15713654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P53 family: at the crossroads in cancer therapy.
    Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
    Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
    Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
    Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships.
    Mantovani F; Zannini A; Rustighi A; Del Sal G
    Biochim Biophys Acta; 2015 Oct; 1850(10):2048-60. PubMed ID: 25641576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.